NRXP

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

NRX Pharmaceuticals Inc

NASDAQ | NRXP

2.95

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$70.12M

Market Cap

-

P/E Ratio

-2.21

EPS

$6.01

52 Week High

$1.10

52 Week Low

HEALTHCARE

Sector

NRXP Chart

Recent Chart
Price Action

NRXP Technicals

Tags:

NRXP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$5K
Total Revenue $0
Cost Of Revenue $5K
Costof Goods And Services Sold $5K
Operating Income -$19M
Selling General And Administrative $14M
Research And Development $6.2M
Operating Expenses $20M
Investment Income Net -
Net Interest Income -$186K
Interest Income $44K
Interest Expense $1.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $5K
Income Before Tax -$25M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$25M
Comprehensive Income Net Of Tax -
Ebit -$24M
Ebitda -$24M
Net Income -$25M

Revenue & Profitability

Earnings Performance

NRXP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $3.7M
Total Current Assets $3.3M
Cash And Cash Equivalents At Carrying Value $1.4M
Cash And Short Term Investments $1.4M
Inventory -
Current Net Receivables -
Total Non Current Assets $349K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.9M
Other Non Current Assets -
Total Liabilities $27M
Total Current Liabilities $22M
Current Accounts Payable $4.1M
Deferred Revenue -
Current Debt -
Short Term Debt $1.6M
Total Non Current Liabilities $5M
Capital Lease Obligations -
Long Term Debt $5M
Current Long Term Debt $1.6M
Long Term Debt Noncurrent -
Short Long Term Debt Total $6.6M
Other Current Liabilities $16M
Other Non Current Liabilities -
Total Shareholder Equity -$23M
Treasury Stock -
Retained Earnings -$278M
Common Stock $15K
Common Stock Shares Outstanding $11M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$11M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $5K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $7.5M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$25M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$5K
Total Revenue $0
Cost Of Revenue $5K
Costof Goods And Services Sold $5K
Operating Income -$19M
Selling General And Administrative $14M
Research And Development $6.2M
Operating Expenses $20M
Investment Income Net -
Net Interest Income -$186K
Interest Income $44K
Interest Expense $1.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $5K
Income Before Tax -$25M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$25M
Comprehensive Income Net Of Tax -
Ebit -$24M
Ebitda -$24M
Net Income -$25M

NRXP News

NRXP Profile

NRX Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

NRx Pharmaceuticals, Inc. (NRXP) is a clinical-stage pharmaceutical company focused on developing innovative therapies for life-threatening central nervous system disorders and lung diseases. Based in Wilmington, Delaware, the company utilizes its proprietary discoveries to address unmet medical needs, leveraging advanced research to create novel treatment options. With a robust pipeline aimed at tackling serious health challenges, NRX Pharmaceuticals is positioned to make significant contributions to the field of medicine as it advances its drug candidates through clinical trials.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
WOK
-5.22%
$0.08
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
WOK
-5.22%
$0.08
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.